

Appendix: Tables

1.	Sales January to March 2022 and 2021	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2022 vs. YTD March 2021	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to March 2022 and 2021

CHF millions	Three months ended 31 March		% change	
	2022	2021	At CER	In CHF
Pharmaceuticals Division	11,159	10,600	6	5
United States	5,489	5,292	2	4
Europe	2,072	2,175	-1	-5
Japan	1,337	852	69	57
International*	2,261	2,281	0	-1
Diagnostics Division	5,286	4,330	24	22
Roche Group	16,445	14,930	11	10

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021

CHF millions	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021
Pharmaceuticals Division	10,600	-9	11,071	4	11,708	5	11,662	14	11,159	6
United States	5,292	-14	5,510	0	5,905	0	5,798	8	5,489	2
Europe	2,175	-6	2,310	15	2,125	1	2,266	19	2,072	-1
Japan	852	-7	956	7	1,378	60	1,320	46	1,337	69
International*	2,281	0	2,295	4	2,300	2	2,278	9	2,261	0
Diagnostics Division	4,330	55	4,712	48	4,263	18	4,455	8	5,286	24
Roche Group	14,930	3	15,783	14	15,971	8	16,117	12	16,445	11

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD March 2022 vs. YTD March 2021

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,449	18	1,050	12	280	34	-	-	119	29
Perjeta	993	1	362	-1	228	-21	59	-1	344	32
Hemlibra	853	30	520	28	170	31	84	15	79	63
Tecentriq	825	8	446	10	183	14	107	-5	89	0
Actemra/RoActemra	792	3	380	22	220	-4	87	12	105	-30
Herceptin	607	-19	144	-26	122	-13	15	-30	326	-18
Ronapreve	587	272	-	-	62	-61	483	-	42	-
Avastin	581	-32	178	-39	58	-56	131	-12	214	-23
MabThera/Rituxan	564	-21	347	-20	54	-19	8	-15	155	-23
Kadcyla	511	9	204	0	172	8	32	28	103	26
Xolair	456	9	456	9	-	-	-	-	-	-
Alecensa	361	23	99	25	75	5	54	7	133	45
Lucentis	256	-26	256	-26	-	-	-	-	-	-
Activase/TNKase	247	-20	234	-21	-	-	-	-	13	-3
Esbriet	241	-6	170	-4	62	-5	-	-	9	-36
Evrysdi	226	189	109	36	68	**	17	-	32	**
Gazyva	165	7	75	0	46	-5	15	8	29	75
Phesgo	146	410	60	187	76	**	-	-	10	**
Pulmozyme	136	-3	87	0	26	-11	-	-	23	-4
CellCept	134	-12	10	-15	34	-7	14	-8	76	-14
Polivy	81	89	34	75	22	4	21	-	4	40
Erivedge	63	6	40	2	15	2	-	-	8	37

Enspryng	41	216	13	**	2	**	25	141	1	425
Vabysmo	21	-	21	-	-	-	-	-	-	-
Rozlytrek	16	78	11	66	2	88	2	49	1	413
Cotellic	12	20	4	31	4	-9	-	-	4	55
Gavreto	5	-	4	-	1	-	-	-	-	-
Xofluza	2	-	1	**	-	-	-	-	1	-
Susvimo	1	-	1	-	-	-	-	-	-	-
Pharma other	787	-12	173	-10	90	-21	183	4	341	-18
Pharma total sales	11,159	6	5,489	2	2,072	-1	1,337	69	2,261	0

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021
Ocrevus	1,226	16	1,212	31	1,283	7	1,334	25	1,449	18
Perjeta	988	2	980	7	1,006	2	981	3	993	1
Hemlibra	661	33	732	58	779	37	850	38	853	30
Tecentriq	775	26	824	31	878	23	838	17	825	8
Actemra/RoActemra	779	22	863	12	1,048	57	872	21	792	3
Herceptin	755	-35	641	-35	665	-26	633	-6	607	-19
Ronapreve	166	-	429	-	489	-	546	-	587	272
Avastin	863	-40	782	-40	745	-37	666	-30	581	-32
MabThera/Rituxan	705	-46	674	-34	589	-42	597	-26	564	-21
Kadcyla	478	17	481	21	501	11	522	16	511	9
Xolair	409	-6	478	3	529	8	526	14	456	9
Alecensa	298	14	333	25	357	18	368	15	361	23
Lucentis	337	-7	328	2	352	-10	336	2	256	-26
Activase/TNKase	304	-17	294	3	323	3	391	22	247	-20
Esbriet	256	-8	270	1	263	-5	250	-7	241	-6
Evrysdi	80	-	163	-	153	*	206	347	226	189
Gazyva	155	-2	169	18	177	10	177	10	165	7
Phesgo	29	-	67	-	117	*	127	*	146	410
Pulmozyme	139	-23	137	-13	138	-7	152	5	136	-3
CellCept	154	-5	144	-3	155	3	139	-2	134	-12

* Over 500%

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021
Ocrevus	914	9	935	28	930	0	998	23	1,050	12
Perjeta	360	-2	343	-3	376	2	337	-2	362	-1
Hemlibra	398	21	439	49	480	36	498	33	520	28
Tecentriq	395	13	416	19	461	10	416	2	446	10
Actemra/RoActemra	305	10	384	3	611	143	461	67	380	22
Herceptin	191	-57	157	-55	153	-52	135	-34	144	-26
Ronapreve	-	-	-	-	-	-	-	-	-	-
Avastin	287	-48	243	-46	215	-50	177	-45	178	-39
MabThera/Rituxan	426	-53	429	-37	342	-49	355	-32	347	-20
Kadcyla	200	5	201	6	212	0	200	3	204	0
Xolair	409	-6	478	3	529	8	526	14	456	9
Alecensa	77	-2	90	13	96	9	103	18	99	25
Lucentis	337	-7	328	2	352	-10	336	2	256	-26
Activase/TNKase	291	-17	279	2	309	2	376	22	234	-21
Esbriet	173	-8	188	0	195	-2	176	-7	170	-4
Evrysdi	79	-	87	-	102	*	97	112	109	36
Gazyva	74	0	79	28	79	3	81	11	75	0
Phesgo	20	-	32	-	46	*	53	236	60	187
Pulmozyme	85	-28	88	-21	89	-10	101	6	87	0
CellCept	11	-31	12	-18	12	-18	10	-31	10	-15

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021
Ocrevus	217	37	205	40	267	36	227	26	280	34
Perjeta	301	-3	277	2	269	-8	265	-8	228	-21
Hemlibra	136	71	156	123	148	26	169	53	170	31
Tecentriq	168	14	171	20	181	16	193	41	183	14
Actemra/RoActemra	239	12	217	20	207	10	252	18	220	-4
Herceptin	146	-25	131	-25	130	-20	137	-3	122	-13
Ronapreve	166	-	317	-	85	-	159	-	62	-61
Avastin	138	-68	119	-69	89	-69	84	-49	58	-56
MabThera/Rituxan	69	-45	65	-21	69	-33	65	-13	54	-19
Kadcyla	167	24	169	29	172	16	179	16	172	8
Xolair	-	-	-	-	-	-	-	-	-	-
Alecensa	74	11	74	19	73	7	76	9	75	5
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	69	-10	68	9	65	0	67	0	62	-5
Evrysdi	-	-	27	-	35	-	51	*	68	*
Gazyva	51	-11	55	19	61	10	56	2	46	-5
Phesgo	7	-	32	-	53	-	71	-	76	*
Pulmozyme	30	-20	30	-7	29	-10	28	-15	26	-11
CellCept	38	-22	39	17	38	-2	39	3	34	-7

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	64	-11	68	-2	68	0	68	-3	59	-1
Hemlibra	79	11	87	21	94	29	105	30	84	15
Tecentriq	120	82	137	86	130	75	131	34	107	-5
Actemra/RoActemra	84	-2	98	15	103	25	97	5	87	12
Herceptin	22	-43	21	-37	20	-37	19	-36	15	-30
Ronapreve	-	-	-	-	360	-	285	-	483	-
Avastin	161	-8	169	0	172	5	172	0	131	-12
MabThera/Rituxan	10	-37	10	-34	11	-30	11	-17	8	-15
Kadcyla	27	54	33	57	34	59	36	42	32	28
Xolair	-	-	-	-	-	-	-	-	-	-
Alecensa	55	8	63	10	63	11	66	5	54	7
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Evrysdi	-	-	-	-	3	-	16	-	17	-
Gazyva	14	1	17	-17	16	10	15	-7	15	8
Phesgo	-	-	-	-	-	-	-	-	-	-
Pulmozyme	0	-23	0	-9	0	-18	1	22	-	-
CellCept	17	-9	18	-7	17	-7	18	-9	14	-8

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021
Ocrevus	95	77	72	41	86	35	109	51	119	29
Perjeta	263	23	292	34	293	16	311	24	344	32
Hemlibra	48	214	50	92	57	138	78	55	79	63
Tecentriq	92	84	100	56	106	62	98	24	89	0
Actemra/RoActemra	151	134	164	27	127	-14	62	-55	105	-30
Herceptin	396	-16	332	-22	362	-7	342	17	326	-18
Ronapreve	-	-	112	-	44	-	102	-	42	-
Avastin	277	-4	251	-20	269	-11	233	-24	214	-23
MabThera/Rituxan	200	-23	170	-30	167	-25	166	-15	155	-23
Kadcyla	84	28	78	35	83	16	107	38	103	26
Xolair	-	-	-	-	-	-	-	-	-	-
Alecensa	92	44	106	59	125	40	123	25	133	45
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	13	-10	15	6	14	17	15	7	13	-3
Esbriet	14	0	14	-7	3	-73	7	-36	9	-36
Evrysdi	1	-	49	-	13	-	42	**	32	**
Gazyva	16	21	18	23	21	43	25	56	29	75
Phesgo	2	-	3	-	18	-	3	**	10	**
Pulmozyme	24	3	19	40	20	12	22	45	23	-4
CellCept	88	11	75	-8	88	13	72	3	76	-14

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%